2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2655

Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 2656

Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Abstract Number: 2657

Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity
Abstract Number: 2658

Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 2659

Respiratory Symptoms in Patients with Primary SjöGren’s Syndrome – a Case-Control Study
Abstract Number: 2660

Do Ultrasonographic Lesions of Salivary Glands Evolve in SjöGren Patients during Follow-up ?
Abstract Number: 2661

Performance of the Proposed ACR-EULAR Criteria for Sjogren’s Syndrome in a Prospective Multidisciplinary Diagnostic Cohort from Daily Clinical Practice
Abstract Number: 2662

Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome
Abstract Number: 2663

Antimalarials Protect Against Damage Accrual in Primary SjöGren’s Syndrome
Abstract Number: 2664

Evaluation of Thyroid Autoimmune Disease in Primary SjöGren’s Syndrome and Its Association with Disease Phenotype
Abstract Number: 2665

Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Abstract Number: 2666

Therapeutic Efficacy of Iguratimod in Patients with Primary Sjogren’s Syndrome
Abstract Number: 2667

Whole Frequency Audiometrical Correlation with Disease Activity in Primary SjöGren’s Syndrome in Hispanic Population
Abstract Number: 2668

Real Time Sonoelastography in Primary Sjögren’s Syndrome Correlates with Morphological Ultrasonographic Features and Glandular Activity but Not with Glandular Fibrosis
Abstract Number: 2669

Biological Treatments in Primary SjöGren Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].